Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tiotropium bromide
Drug ID BADD_D02224
Description Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than [ipratropium].[A180163] Tiotropium was granted FDA approval on 30 January 2004.[L7084]
Indications and Usage Used in the management of chronic obstructive pulmonary disease (COPD).
Marketing Status Prescription
ATC Code R03BB04
DrugBank ID DB01409
KEGG ID D01929
MeSH ID D000069447
PubChem ID 5487426
TTD Drug ID D0P1WA
NDC Product Code 54239-011; 0597-0075; 50090-4414; 50090-4248; 58175-0565
Synonyms Tiotropium Bromide | Bromide, Tiotropium | 7-((hydroxybis(2-thienyl)acetyl)oxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane bromide | Tiotropium | Spiriva | BA 679 BR | 679 BR, BA | BR, BA 679 | BA-679 BR | BA679 BR
Chemical Information
Molecular Formula C19H22BrNO4S2
CAS Registry Number 136310-93-5
SMILES C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C.[Br-]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tonsillitis22.07.03.008; 11.01.13.006--Not Available
Type I hypersensitivity10.01.03.006--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urethral disorder20.07.01.002--Not Available
Urinary retention20.02.02.011--
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Ventricular tachycardia02.03.04.010--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Cardiac death02.03.04.015; 08.04.01.007--Not Available
Oropharyngeal candidiasis22.07.03.003; 11.03.03.006; 07.05.07.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Angiopathy24.03.02.007--Not Available
Connective tissue disorder15.06.01.006--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Urinary tract obstruction20.08.01.004--
Supraventricular tachyarrhythmia02.03.03.014--Not Available
Oropharyngeal discomfort22.02.05.027; 07.05.05.008--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Candida infection11.03.03.021--
The 4th Page    First    Pre   4    Total 4 Pages